NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 21, 2020 / In accordance with Rule 2.9 of the Takeover Code, Midatech confirms that, as at the date of this announcement, it has 32,585,891 ordinary shares with par value £0.001 in issue ('Ordinary Shares') and admitted to trading on the AIM market of the London Stock Exchange with International Securities Identification Number GB00BKT14T00. The Company has an American Depositary Receipts facility with respect to its American Depositary Shares ('ADSs', where each ADS represents 5 Ordinary Shares) with 2,711,368 ADSs currently outstanding as of 20 May 2020, representing 13,556,840 Ordinary Shares. The ADSs are registered with the US Securities and Exchange Commission ('SEC') and are listed on The NASDAQ Capital Market with International Securities Identification Number US59564R3021.
For more information, please contact:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
SOURCE: Midatech Pharma PLC
View source version on accesswire.com: